Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz Acquires 95,279 Shares of Stock

Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz acquired 95,279 shares of Veru stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the purchase, the director now directly owns 195,279 shares of the company’s stock, valued at $107,403.45. This represents a 95.28 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Veru Stock Down 1.7 %

NASDAQ VERU opened at $0.59 on Friday. The business has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $0.76. Veru Inc. has a one year low of $0.47 and a one year high of $1.92.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. On average, equities analysts predict that Veru Inc. will post -0.22 EPS for the current year.

Analysts Set New Price Targets

VERU has been the topic of several research reports. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Veru in a research note on Thursday, January 2nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VERU. MPM Bioimpact LLC bought a new stake in Veru in the fourth quarter valued at $2,788,000. Oppenheimer & Co. Inc. increased its position in Veru by 181.6% in the 4th quarter. Oppenheimer & Co. Inc. now owns 1,120,586 shares of the company’s stock valued at $729,000 after buying an additional 722,644 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Veru by 337.4% during the 4th quarter. JPMorgan Chase & Co. now owns 255,782 shares of the company’s stock worth $166,000 after buying an additional 197,307 shares during the period. Barclays PLC boosted its holdings in Veru by 309.2% in the third quarter. Barclays PLC now owns 184,777 shares of the company’s stock worth $142,000 after acquiring an additional 139,617 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Veru by 4.7% in the third quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company’s stock valued at $2,261,000 after acquiring an additional 131,720 shares during the period. 47.16% of the stock is owned by institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.